{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:25:02Z","timestamp":1772133902663,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.ijpharm.2005.09.006","type":"journal-article","created":{"date-parts":[[2005,11,8]],"date-time":"2005-11-08T07:14:46Z","timestamp":1131434086000},"page":"122-131","source":"Crossref","is-referenced-by-count":21,"title":["Enhancement of brain distribution of anticancer agents using \u0394G, the 12kDa active fragment of ZOT"],"prefix":"10.1016","volume":"306","author":[{"given":"Divya","family":"Menon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan S.","family":"Karyekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruliang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie D.","family":"Eddington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2005.09.006_bib1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jps.2600790604","article-title":"Epithelial transport of drugs in cell culture. I. A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells","volume":"79","author":"Artursson","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib2","first-page":"1372","article-title":"Transport and matabolism of sleep inducing peptide in cultured human intestinal epithelial cell monolayers","volume":"23","author":"Augustijins","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01062139","article-title":"Testing for the equality of areas under the curves when using destructive measurement techniques","volume":"16","author":"Bailer","year":"1988","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/ctrv.2000.0194","article-title":"The blood\u2013brain barrier and oncology: new insights into function and modulation","volume":"26","author":"Bart","year":"2000","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0140-6736(03)12328-8","article-title":"Primary brain tumours in adults","volume":"361","author":"Behin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib6","first-page":"53","article-title":"Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol)","volume":"21","author":"Beijnen","year":"1994","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: the multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib8","first-page":"186","article-title":"The structure and function of the blood\u2013brain barrier","volume":"43","author":"Bradbury","year":"1984","journal-title":"Fed. Proc."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib9","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1158\/0008-5472.CAN-03-4062","article-title":"Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug\u2013drug interactions","volume":"64","author":"Breedveld","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0378-4347(00)80513-7","article-title":"High performance liquid chromatographic assay of methotrexate, 7-hydroxymethotrxate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid","volume":"231","author":"Cairnes","year":"1982","journal-title":"J. Chromatogr.: Biomed. Appl."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib11","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2409::AID-CNCR17>3.0.CO;2-V","article-title":"Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?","volume":"79","author":"Corn","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib12","first-page":"6225","article-title":"Blood\u2013brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats","volume":"47","author":"Cosolo","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/88.10.675","article-title":"Epidemiology of brain lymphoma among people with or wihtout accquired immunodeficiency syndrome","volume":"88","author":"Cote","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0939-6411(01)00172-2","article-title":"Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin","volume":"52","author":"Cox","year":"2001","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib15","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1023\/A:1020709513562","article-title":"Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin","volume":"19","author":"Cox","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib16","first-page":"386","article-title":"Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation","volume":"54","author":"Cresteil","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib17","doi-asserted-by":"crossref","first-page":"19160","DOI":"10.1074\/jbc.M009674200","article-title":"Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain","volume":"276","author":"Di Pierro","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib18","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1073\/pnas.88.12.5242","article-title":"Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions","volume":"88","author":"Fasano","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1172\/JCI118114","article-title":"Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro","volume":"96","author":"Fasano","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib20","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1172\/JCI119271","volume":"99","author":"Fasano","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib21","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1172\/JCI119271","article-title":"Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model","volume":"99","author":"Fasano","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1053\/gast.1997.v112.pm9041245","article-title":"The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway","volume":"112","author":"Fasano","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1172\/JCI0215451","article-title":"Transport of paclitaxel (Taxol) across the blood\u2013brain barrier in vitro and in vivo","volume":"110","author":"Fellner","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002329900434","article-title":"Blood\u2013brain barrier permeation: molecular parameters governing passive diffusion","volume":"165","author":"Fischer","year":"1998","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib25","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/jps.10424","article-title":"Blood\u2013brain barrier efflux transport","volume":"92","author":"Golden","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib26","first-page":"4026","article-title":"Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme","volume":"54","author":"Harris","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0065-2571(94)90025-6","article-title":"The methotrexate story: a paradigm for development of cancer chemotherapeutic agents","volume":"34","author":"Huennekens","year":"1994","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3171\/jns.1994.81.5.0752","article-title":"Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors","volume":"81","author":"Inamura","year":"1994","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib29","series-title":"Proceedings of the 17th National Meeting on Annual American Association of Pharmaceutical Scientists","author":"Karyekar","year":"2002"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib30","series-title":"Proceedings of the 17th National Meeting on Annual American Association of Pharmaceutical Scientists","author":"Karyekar","year":"2002"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jps.10310","article-title":"Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells","volume":"92","author":"Karyekar","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib32","first-page":"2849","article-title":"Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein","volume":"9","author":"Kemper","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/00006123-199805000-00082","article-title":"Outwitting the blood\u2013brain barrier for therapeutic purposes: osmotic opening and other means","volume":"42","author":"Kroll","year":"1998","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/00006123-199810000-00090","article-title":"Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood\u2013brain and\/or blood\u2013tumor barriers","volume":"43","author":"Kroll","year":"1998","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib35","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/jnci\/91.16.1382","article-title":"Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality","volume":"91","author":"Legler","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00685646","article-title":"The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study","volume":"37","author":"Lesser","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib37","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1021\/jm00180a022","article-title":"Relationship of octanol\/water partition coefficient and molecular weight to rat brain capillary permeability","volume":"23","author":"Levin","year":"1980","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib38","unstructured":"Louis, D.N., Posner, J., Jacobs, T., Kaplan, R., 2000. Report of the Brain Tumor Progress Review Group. National Cancer Institute, National Institute of Neurological Disorders and Stroke, pp. 19\u201320."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1471-4159.2000.0740320.x","article-title":"Affinity purification and partial characterization of the zonulin\/zonula occludens toxin (Zot) receptor from human brain","volume":"74","author":"Lu","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib40","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/js970134j","article-title":"Molecular structure of the apical junction complex and its contribution to the paracellular barrier","volume":"86","author":"Lutz","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000408237","article-title":"Therapeutic potential for blood\u2013brain barrier modification in malignant brain tumor","volume":"28","author":"Neuwelt","year":"1984","journal-title":"Prog. Exp. Tumor Res."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib42","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.1991.9.9.1580","article-title":"Primary CNS lymphoma treated with osmotic blood\u2013brain barrier disruption: prolonged survival and preservation of cognitive function","volume":"9","author":"Neuwelt","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00004647-199707000-00001","article-title":"Drug delivery to the brain","volume":"17","author":"Pardridge","year":"1997","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1254\/jjp.87.97","article-title":"Brain drug targeting and gene technologies","volume":"87","author":"Pardridge","year":"2001","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib45","doi-asserted-by":"crossref","DOI":"10.1124\/mi.3.2.90","article-title":"Blood\u2013brain barrier drug targeting: the future of brain drug development","volume":"3","author":"Pardridge","year":"2003","journal-title":"Mol. Interv."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib46","first-page":"884","article-title":"Comparison of in vitro and in vivo models of drug transcytosis through the blood\u2013brain barrier","volume":"253","author":"Pardridge","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/neuonc\/5.2.96","article-title":"A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma","volume":"5","author":"Prados","year":"2003","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib48","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1002\/1097-0142(19880615)61:12<2423::AID-CNCR2820611205>3.0.CO;2-H","article-title":"The safety of administration of massive doses of methotrexate (50g) with equimolar citrovorum factor rescue in adult patients","volume":"61","author":"Reggev","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1385\/JMN:20:3:339","article-title":"Overcoming the blood\u2013brain barrier to taxane delivery for neurodegenerative diseases and brain tumors","volume":"20","author":"Rice","year":"2003","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev.neuro.22.1.11","article-title":"The cell biology of the blood\u2013brain barrier","volume":"22","author":"Rubin","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0378-5173(02)00589-6","article-title":"Effect of the biologically active fragment of zonula occludens toxin, \u0394G, on the intestinal paracellular transport and oral absorption of mannitol","volume":"251","author":"Salama","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib52","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/jps.20052","article-title":"The effect of \u0394G on the transport and oral absorption of macromolecules","volume":"93","author":"Salama","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/jpet.104.073205","article-title":"The impact of \u0394G on the oral bioavailability of low bioavailable therapeutic agents","volume":"312","author":"Salama","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000137531","article-title":"Pharmacokinetics and organ distribution of methotrexate in the rat","volume":"23","author":"Scheufler","year":"1981","journal-title":"Pharmacology"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3171\/jns.2000.92.4.0599","article-title":"In vivo assessment of the window of barrier opening after osmotic blood\u2013brain barrier disruption in humans","volume":"92","author":"Siegal","year":"2000","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00003088-200241030-00002","article-title":"Strategies for increasing drug delivery to the brain: focus on brain lymphoma","volume":"41","author":"Siegal","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF01733202","article-title":"Blood\u2013brain barrier and the penetration of cytostatic drugs","volume":"63","author":"Unger","year":"1985","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.ijpharm.2005.09.006_bib58","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/bjc.1997.530","article-title":"Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833","volume":"76","author":"van Asperen","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijpharm.2005.09.006_bib59","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1021\/js990174i","article-title":"Blood\u2013brain properties of human immunodeficiency virus antiretrovirals","volume":"88","author":"Yazdanian","year":"1999","journal-title":"J. Pharm. Sci."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517305006010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517305006010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T07:55:40Z","timestamp":1554364540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517305006010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":59,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0378517305006010"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2005.09.006","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}